You are here

Expression of Anaplasma marginale major surface protein 2 variants during persistent cyclic rickettsemia.

TitleExpression of Anaplasma marginale major surface protein 2 variants during persistent cyclic rickettsemia.
Publication TypeJournal Article
Year of Publication1998
AuthorsFrench, DM, McElwain, TF, McGuire, TC, Palmer, GH
JournalInfect Immun
Volume66
Issue3
Pagination1200-7
Date Published1998 Mar
ISSN0019-9567
KeywordsAmino Acid Sequence, Anaplasmosis, Animals, Bacteremia, Bacterial Proteins, Cattle, Molecular Sequence Data, Polymorphism, Genetic, RNA, Messenger
Abstract

Anaplasma marginale is an intraerythrocytic rickettsial pathogen of cattle in which infection persists for the life of the animal. Persistent A. marginale infection is characterized by repetitive rickettsemic cycles which we hypothesize reflect emergence of A. marginale antigenic variants. In this study, we determined whether variants of major surface protein 2 (MSP-2), a target of protective immunity encoded by a polymorphic multigene family, arise during persistent rickettsemia. By using a quantitative competitive PCR to identify rickettsemic cycles, msp-2 transcripts expressed in vivo were isolated from peak rickettsemia of sequential cycles. Cloning and sequencing of msp-2 cDNA revealed that genetic variants of MSP-2 emerge representing a minimum of four genetic variant types in each cycle during persistent infection. Two-color immunofluorescence using variant-specific antibody showed that emergence of MSP-2 variants resulted in expression of a minimum of three antigenic types of MSP-2 within one rickettsemic cycle. Therefore immune control of each cycle would require responses to an antigenically diverse A. marginale population. These findings demonstrate that polymorphic MSP-2 variants emerge during cyclic rickettsemia in persistent A. marginale infection and suggest that emergent variants play an important role in persistence.

Alternate JournalInfect. Immun.
PubMed ID9488414
PubMed Central IDPMC108034
Grant List5 K08 AI01371-02 / AI / NIAID NIH HHS / United States